BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17619159)

  • 1. Screening for prostate cancer using prostate-specific antigen testing in Japanese men on hemodialysis.
    Kurahashi T; Miyake H; Shinozaki M; Oka N; Takenaka A; Hara I; Matsumura Y; Fujisawa M
    Int Urol Nephrol; 2008; 40(2):345-9. PubMed ID: 17619159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening with prostate-specific antigen in hemodialysis patients.
    Horinaga M; Kitamura K; Saito S; Ukimura O; Nakanoma T; Okihara K; Kitagawa M; Nakanishi H; Miki T
    Urol Int; 2007; 78(4):334-7. PubMed ID: 17495492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
    Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
    BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study.
    Wada Y; Nakanishi J; Takahashi W; Kai N; Nakayama Y; Yamashita Y; Honda J; Ueda S
    BJU Int; 2006 Oct; 98(4):794-7. PubMed ID: 16978274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass screening of prostate cancer in Changchun City of China.
    Li X; Tsuji I; Kuwahara M; Zhang H; Wang H; Zhang L; Ji G; Zhao X
    Int Urol Nephrol; 2004; 36(4):541-8. PubMed ID: 15787333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mass screening for prostate cancer in Tokushima City: the results of 2001].
    Kanayama HO; Kagawa S; Utsunomiya M; Kawashima S; Takehisa I; Sumitani H; Yokozeki H
    Nihon Hinyokika Gakkai Zasshi; 2004 Mar; 95(3):596-603. PubMed ID: 15103922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of serum prostate-specific antigen in hemodialysis patients.
    Sumura M; Yokogi H; Beppu M; Honda H
    Int J Urol; 2003 May; 10(5):247-50. PubMed ID: 12694463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population.
    Kobayashi T; Mitsumori K; Kawahara T; Nishizawa K; Ogura K; Ide Y
    J Urol; 2006 Apr; 175(4):1281-5. PubMed ID: 16515980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.
    Babaian RJ; Johnston DA; Naccarato W; Ayala A; Bhadkamkar VA; Fritsche HA HA
    J Urol; 2001 Mar; 165(3):757-60. PubMed ID: 11176461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening program of prostate cancer at Tokai University Hospital: characterization of prostate-specific antigen measurement.
    Tokunaga M; Yasuda M; Miyakita H; Kawamura Y; Shoji S; Sasaki H; Kono T; Kobayashi Y; Shima M; Usui Y; Masuda A; Kinoshita H; Ogawa T; Honma Y; Osamura RY; Terachi T
    Tokai J Exp Clin Med; 2005 Jul; 30(2):103-10. PubMed ID: 16146200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
    Dyche DJ; Ness J; West M; Allareddy V; Konety BR
    J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostate cancer detection by prostate biopsy among Japanese with prostate-specific antigen below 4.0 ng/ml].
    Kanno T; Shibasaki N; Tsuji Y; Taki Y; Takeuchi H
    Hinyokika Kiyo; 2006 Mar; 52(3):181-4. PubMed ID: 16617870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
    Catalona WJ; Smith DS; Ratliff TL; Dodds KM; Coplen DE; Yuan JJ; Petros JA; Andriole GL
    N Engl J Med; 1991 Apr; 324(17):1156-61. PubMed ID: 1707140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
    BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.